To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients.
We measured the insulin sensitivity index (SI), determined by the Minimal Model Method of Bergman, fasting plasma insulin and glucose concentrations, serum total triglyceride and lipoprotein cholesterol fractions, and blood pressure in 20 obese, non-diabetic patients with essential hypertension before and after 6 weeks of placebo and again after 6 months of amlodipine. Ten patients [mean body mass index (BMI) 30.2 kg·m−2] had been on prior treatment with a thiazide diuretic in low dosage and/or a β-adrenoceptor blocker (group A), and 10 matched patients [BMI 31.8 kg·m−2] had been previously untreated (group B). Amlodipine was started in a dose of 5 mg and was increased to 10 mg once daily in 14 patients who were hypertensive after 8 weeks on the lower dosage.
At entry (before placebo), SI was slightly but not significantly lower in group A than B [2.7 vs. 3.6×10−4 ml·μU−4·min−1]; fasting plasma insulin was 13.6 vs. 12.9 μU·ml−1. After 6 weeks on placebo, SI averaged 3.7 in group A and 4.4×10−4 μU·ml−1·min−1 in group B; fasting plasma insulin was 14.6 vs. 15.1 μU·ml−1, and glucose 5.5 vs. 5.5 mmol·l−1. After 6 months on amlodipine there were no differences in SI [group A vs. group B, 5.2 vs. 3.8×10−4 ml·μU−1·min−1], fasting insulin [13.0 vs. 12.7 μU·ml−1], glucose [5.4 vs. 5.5 mmol·l−1], serum total triglycerides, and cholesterol or lipoprotein cholesterol fractions. Compared with placebo, amlodipine significantly reduced systolic and diastolic blood pressures. Heart rate, body weight, and 24 h urinary sodium excretion were unaltered.
Long-term treatment with amlodipine does not affect insulin sensitivity, circulating insulin or glucose, or lipoprotein metabolism in obese, non-diabetic patients with essential hypertension.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Ferranini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S (1987) Insulin resistance in essential hypertension. New Engl J Med 1987 317: 350–357
Pyörälä K, Savolainen E, Kaukola S, Haapakoski J (1985) Plasma insulin as coronary heart disease factor: relationship to other risk factors and predictive value during 9.5-year follow-up of the Helsinki Policemen Study Population. Acta Med Scand 701 [Suppl]: 38–52
Stokes J, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB (1987) The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75 [Suppl V]: 65–73
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlin KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet I: 827–838
Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment of insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 [Suppl 4]: 39–47
Ferrari P, Rosman J, Weidmann P (1991) Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 67: 26B-35B
Weidmann P, de Courten M, Ferrari P (1993) Effect of diuretics on the plasma lipid profile. Eur Heart J (in press)
Morgan KG (1987) Calcium and vascular smooth muscle tone. Am J Med 82 [Suppl 3 B]: 9–15
Wollheim CB, Sharp GWG (1981) Regulation of insulin release by calcium. Physiol Rev 61: 914–973
Draznin B, Sussman K, Kao M, Lewis D, Sherman N (1987) The existance of an optimal of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem 262: 14385–14388
Pershadsingh HA, Shade DL, Delfert DM, McDonald JM (1987) Chelation of intracellular calcium blocks insulin action in adipocyte. Proc Natl Acad Sci USA 84: 1025–1029
Trost BN, Weidmann P (1988) Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium and uric acid homeostasis. J Cardiovasc Pharmacol 12 [Suppl 6]: S 86-S 92
Weidmann P, Boehlen LM, de Courten M (1993) Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J (in press)
Charles S, Ketelslegers JM, Buysschaert M, Lambert AE (1981) Hyperglycaemic effect of nifedipine. Br Med J 283: 19–20
Bhatnagar SK, Amin MAA, Al-Yusuf AR (1984) Diabetogenic effects of nifedipine. Br Med J 289: 19
Ferrari P, Giachino D, Weidmann P, Shaw S, Riesen W, Neuner N, Keller U, Heynen G (1991) Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur J Clin Pharmacol 41: 109–113
Murdoch D, Heel RC (1991) Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 41: 478–505
Nuttall FQ, Gannon MC, Wald JL, Ahmed M (1985) Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content. J Am Coll Nutr 4: 437–450
Bergman RN, Prager R, Volund A, Olefsky JM (1987) Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790–800
Yang YJ, Youn JH, Bergman RN (1987) Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 253: E595-E602
Kruse W, Weber E (1990) Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 38: 561–565
Ferrari P, Allemann Y, Shaw S, Riesen W, Weidmann P (1991) Reproducibility of insulin sensitivity measured by the minimal model method. Diabetologia 34: 527–530
Ferrari P, Weidmann P, Shaw SG, Giachino D, Riesen W, Alleman Y, Heynen G (1991) Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in hypertension-prone humans. Am J Med 91: 589–596
Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G (1990) Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II. Eur J Clin Pharmacol 41: 109–113
Manual of laboratory operations. Lipid Research Clinics Program (1974) Lipid and lipoprotein analysis (publication NIH) 75–628 US Department of Health, Education of Welfare, US Government Printing Office, Washington DC
DeFronzo RA, Ferrannini E (1991) Insulin resistance a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–94
Allemann Y, Horber FF, Colombo M, Ferrari P, Shaw S, Jaeger P, Weidmann P (1993) Decreased insulin sensitivity in normotensive offspring of hypertensive parents precedes gain or redistribution of body fat. Lancet I: 327–331
Istfan NW, Plaisted CS, Bistrian BR, Blackburn GL (1992) Insulin resistance versus insulin secretion in the hypertension of obesity. Hypertension 19: 385–92
Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157
Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S (1989) Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hpertens 7: 551–559
Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395–398
Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J (1989) The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens 3: 35–39
Kihara A (1991) Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion. Am Heart J 122: 363–369
Rojdmark S, Andersson DEH (1986) Influence on verapamil on human glucose tolerance. Am J Cardiol 57: 39 D-43 D
Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA (1988) Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinaemia. J Clin Invest 82: 1848–1852
Ferrari P, Weidmann P (1990) Insulin, insulin sensitivity and hypertension. J Hypertens 8: 491–500
Abrams JJ, Ginsberg H, Grundy SM (1982) Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31: 903–910
Taskinen MR, Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H (1988) Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8: 168–177
Reaven GM, Banting lecture 1988 (1988) Role of insulin resistance in human disease. Diabetes 37: 1595–1607
Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinaemia and normal glucose tolerance. New Engl J Med 320: 702–706
Carlsen JE, Kober L, Torp-Pedersen C, Johansen P (1990) Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 300: 975–978
Rights and permissions
About this article
Cite this article
de Courten, M., Ferrari, P., Schneider, M. et al. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 44, 457–462 (1993). https://doi.org/10.1007/BF00315543
- Insulin sensitivity
- lipoprotein metabolism
- obese hypertensive patients